Key events, in time order
New global ion-channel discovery pact adds upfront cash, milestones and royalties
New global ion-channel discovery pact adds upfront cash, milestones and royalties
None yet
None yet
OmniAb is a compelling biotech company with a significant royalty on ramantamig, a potential blockbuster drug, and a new collaboration with Eli Lilly. The stock is experiencing upward momentum following the Eli Lilly deal.
Main discussion
bullish on $OABI - run by Matt Foehr who i dealt with almost 20 years ago at $LGND - Matt's built a really compelling company. announced a $LLY deal today, but the crown jewel is a royalty on ramantamig, which could be one of the biggest drugs of all time. price target: $15
Pre-Market Update ⦿ $OABI up 22% after inking a collaboration/license deal with $LLY for a new ion channel program; upfront payment plus up to $370M in milestones and royalties. ⦿ $KEEL up 8%; , extending recent CEO insider-buying strength. ⦿ $SNDK up 5% as the China memory-chip
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
